Curatis Holding AGXSWX:CURN +3.51%33 Current Ratio is 1.65 as of Dec. 2025, which is 30% above its 10-year median of 1.27. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 7 warning signs investors should review. Among 997 Drug Manufacturers companies, Curatis Holding AG ranks worse than 61.38% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Curatis Holding AG's current ratio for the quarter that ended in Dec. 2025 was 1.65.
Curatis Holding AG has a current ratio of 1.65. It generally indicates good short-term financial strength.
The historical rank and industry rank for Curatis Holding AG's Current Ratio or its related term are showing as below:
XSWX:CURN'
s Current Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.27 Max: 1.81
Current: 1.65
During the past 5 years, Curatis Holding AG's highest Current Ratio was 1.81. The lowest was 0.40. And the median was 1.27.
XSWX:CURN's Current Ratio is ranked worse than 61.38% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs XSWX:CURN: 1.65
Curatis Holding AG (XSWX:CURN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Curatis Holding AG Current Ratio Related Terms
Curatis Holding AG Current Ratio Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CURN vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curatis Holding AG (XSWX:CURN) has a Current Ratio of 1.65 as of Dec. 2025. This is 30% above median its historical median of 1.27. Over the past decade, Curatis Holding AG's Current Ratio has ranged from 0.40 to 1.81. According to the industry distribution chart, Curatis Holding AG ranks #612 out of 997 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Curatis Holding AG's Current Ratio too high?
Curatis Holding AG's current Current Ratio of 1.65 is 30% above median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 1.81. The Drug Manufacturers industry median Current Ratio is 2.00. Curatis Holding AG's value of 1.65 is 17.5% below this industry median. Based on the distribution chart, Curatis Holding AG ranks #612 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #612 out of 997 companies for Current Ratio. This places Curatis Holding AG in the lower half of its industry. The industry median Current Ratio is 2.00. Curatis Holding AG's value of 1.65 is 17.5% below this benchmark. Historically, Curatis Holding AG's own Current Ratio has ranged from 0.40 to 1.81 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 2.00, Curatis Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curatis Holding AG's current Current Ratio of 1.65 is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current Current Ratio is 1.65, which is 30% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current Current Ratio of 1.65. The current Current Ratio is 1.65, which is 30% above median its 10-year median of 1.27 and 17.5% below the Drug Manufacturers industry median of 2.00. Curatis Holding AG's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current Current Ratio is 1.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score
Get the complete analysis for XSWX:CURN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
